Drug Evaluation Committee Utilization of Digital Biomarkers (dBM) in Drug Development and Requirements Document
Clinical Evaluation Subcommittee
Utilization of and Requirements for Digital Biomarkers (dBM) in Drug Development
- About JPMA
- About Pharmaceuticals
- Information from the Committee
Information from the Committee Top
- Code Compliance Committee
- Pharmaceutical Industrial Policy Committee
- Distribution Improvement Committee
- Drug Evaluation Committee
- Quality & Technology Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- R&D Committee
- International Affairs Committee
- Public Affairs Committee
- Patient Cooperation Committee
- ICH Project
- APAC Project
- Consumer Consultation Review Committee
- Environmental Issue Committee
- Newsletter
- News Room
- The Office of Pharmaceutical Industry Research
- For Patients and the Public (About Pharmaceuticals)
-
Information from the Committee
- Code Compliance Committee
- Pharmaceutical Industrial Policy Committee
- Distribution Improvement Committee
- Drug Evaluation Committee
- Quality & Technology Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- R&D Committee
- International Affairs Committee
- Public Affairs Committee
- Patient Cooperation Committee
- ICH Project
- APAC Project
- Consumer Consultation Review Committee
- Environmental Issue Committee
- About JPMA
- Policies and Activities
-
Voluntary Standards
- Charter of Conduct
- JPMA Code of Practice
- Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
- Transparency Guideline for Relationships between Corporate Activities and Patient Groups
- Guidelines for the Preparation of Product Information Summaries for Ethical Drugs (Abbreviated name: Preparation Guidelines)
- Clinical Research
- Basic Philosophy and Action Guidelines on Biodiversity
- Guidelines Concerning Appropriate Competition in Japan Pharmaceutical Manufacturers Association Meetings
- Guidelines for the Promotion of Pharmaceutical Industry in Japan
- News Room
-
The Office of Pharmaceutical Industry Research
- Social Media Policy
- Website Terms of Use
- Vision, Policy Proposals